Get the Stockscreener App
0.3434
2.00%
0.00672
Petros Pharmaceuticals Inc stock is traded at $0.3434, with a volume of 67,542.
It is up +2.00% in the last 24 hours and down -3.27% over the past month.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on therapeutics that promote medication adherence, tolerability, and preservation of male organic function. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists of operations related to vacuum erection devices, which are sold domestically and internationally.
See More
Previous Close:
$0.3367
Open:
$0.33
24h Volume:
67,542
Relative Volume:
0.41
Market Cap:
$3.24M
Revenue:
$6.98M
Net Income/Loss:
$-12.70M
P/E Ratio:
-0.0323
EPS:
-10.64
Net Cash Flow:
$-6.94M
1W Performance:
-9.68%
1M Performance:
-3.27%
6M Performance:
-51.86%
1Y Performance:
-75.65%
1-Day Range:
$0.3223
$0.3535
1-Week Range:
$0.3169
$0.399
52-Week Range:
$0.2821
$2.27
Petros Pharmaceuticals Inc Stock (PTPI) Company Profile
Name
Petros Pharmaceuticals Inc
Sector
Phone
973-242-0005
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
Petros Pharmaceuticals Inc Stock (PTPI) Latest News
Petros Pharmaceuticals Amends President’s Employment Terms - Yahoo Finance
Petros Pharmaceuticals adjusts executive's salary and terms - Investing.com India
Petros Pharmaceuticals adjusts executive's salary and terms By Investing.com - Investing.com South Africa
Petros Pharmaceuticals amends preferred stock terms - Investing.com India
Petros Pharmaceuticals amends preferred stock terms By Investing.com - Investing.com UK
Petros Pharmaceuticals sees two board members resign By Investing.com - Investing.com Australia
Petros Pharmaceuticals sees two board members resign - Investing.com India
Board Reshuffle at Petros Pharmaceuticals Following Resignations - TipRanks
Petros Pharmaceuticals, Inc. Announces Board Resignations - Marketscreener.com
Otsuka and Lundbeck Announce Barbara Corcoran Led Campaign to Raise Awareness of Alzheimer’s Dementia - Pharmaceutical Executive
Petros Pharmaceuticals sets date for 2024 annual meeting - Investing.com
Petros Pharmaceuticals reports high comprehension in drug app study - Investing.com
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) - AccessWire
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - AccessWire
A History of Outperforming Analyst Forecasts and Beating the Odds: Petros Pharmaceuticals Inc (PTPI) - SETE News
Analytical Overview: Petros Pharmaceuticals Inc (PTPI)’s Ratios Tell a Financial Story - The Dwinnex
A stock that deserves closer examination: Petros Pharmaceuticals Inc (PTPI) - US Post News
Petros Pharmaceuticals stock hits 52-week low at $0.28 - Investing.com India
Petros Pharmaceuticals stock hits 52-week low at $0.28 By Investing.com - Investing.com Canada
Petros Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 - MSN
Petros Pharmaceuticals (NASDAQ:PTPI) Stock Price Down 10.4% - Defense World
Petros Pharmaceuticals stock hits 52-week low at $0.37 - Investing.com
Joel Baglole - InvestorPlace
Closing Figures: Petros Pharmaceuticals Inc (PTPI)’s Negative Finish at 0.41, Down -3.55 - The Dwinnex
Petros Pharmaceuticals reports promising Web App study - Investing.com
PTPI’s Market Whiplash: -70.74% YTD Decline, -7.41% Plunge in 30 Days - The InvestChronicle
Petros Pharmaceuticals Inc (NASDAQ:PTPI) stock: Is this a flash in the pan today? - US Post News
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) - AccessWire
Petros Pharma (NASDAQ:PTPI) Stock Quotes, Forecast and News Summary - Benzinga
Get in on Petros Pharmaceuticals Inc’s (PTPI) buy-in window today! - SETE News
Financial Metrics Exploration: Understanding Petros Pharmaceuticals Inc (PTPI) Through Ratios - The Dwinnex
Petros reports successful study for STENDRA OTC switch By Investing.com - Investing.com Canada
Petros Pharmaceuticals Inc Inc. (PTPI) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Petros reports successful study for STENDRA OTC switch - Investing.com
Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance - AccessWire
Quarterly Metrics: Quick and Current Ratios for Petros Pharmaceuticals Inc (PTPI) – DWinneX - The Dwinnex
Can you still get a good price for Petros Pharmaceuticals Inc (PTPI) Shares at this point? - US Post News
Pioneering change: male contraceptives and the coming OTC revolution - Interesting Engineering
The future of health: male contraceptives and OTC innovation - Interesting Engineering
PTPI’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Erectile Dysfunction Drugs Market Size, Share, and Trends 2024 to 2033 - Precedence Research
Petros Pharmaceuticals Inc (PTPI)'s Market Momentum: Closing Strong at 0.41, Down -2.50 – DWinneX - The Dwinnex
Petros Pharmaceuticals Inc (PTPI) did well last session? – US Post News - US Post News
EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros ... - AOL
'The Prescription Erectile Dysfunction Market Could Triple if an ED Therapy Becomes Available - The Bharat Express News
EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says - Benzinga
Stock Surge: Petros Pharmaceuticals Inc (PTPI) Closes at 0.46, Marking a -13.70 Increase/Decrease – DWinneX - The Dwinnex
Healthy Upside Potential: Petros Pharmaceuticals Inc (PTPI) – Sete News - SETE News
Why Broadcom Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving PremarketBroadcom (NASDAQ ... - Benzinga
Petros Pharmaceuticals Inc Stock (PTPI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):